Related Experiment Video

Updated: May 23, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Chitinase 3-like 1 gene-329G/A polymorphism, plasma concentration and risk of coronary heart disease in a Chinese

Fangyi Xie1, Qi Qian, Zhong Chen

  • 1Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, PR China. xiefangyi@sina.com

Gene
|March 22, 2012
PubMed

Insights

The chitinase-like 1 gene variant rs10399931 does not appear to increase susceptibility to coronary heart disease (CHD). However, elevated YKL-40 levels are linked to CHD and its clinical phenotypes.

Area of Science:

  • Cardiovascular Genetics
  • Biomarkers in Cardiology
  • Inflammation and Disease

Background:

  • Chitinase-like 1 protein (YKL-40) is implicated in inflammation and tissue remodeling.
  • Elevated serum YKL-40 levels are observed in patients with coronary heart disease (CHD) and acute myocardial infarction.
  • The study investigates the role of the chitinase-like 1 gene-329G/A variant (rs10399931) in CHD susceptibility and clinical presentation.

Purpose of the Study:

  • To determine if the chitinase-like 1 gene-329G/A variant (rs10399931) confers susceptibility to coronary heart disease (CHD).
  • To assess the association between rs10399931 and the clinical phenotype and severity of CHD.
  • To evaluate plasma YKL-40 levels in relation to CHD and its subtypes.

Main Methods:

  • A case-control study involving 410 CHD patients and 442 controls from China.
  • Genotyping of the rs10399931 single-nucleotide polymorphism using ligase detection reaction.
  • Measurement of plasma YKL-40 levels via ELISA assays and assessment of coronary lesion severity using Gensini scores.

Main Results:

  • No significant differences in genotypic or allelic frequencies of rs10399931 were found between CHD cases and controls.
  • Patients with CHD exhibited higher plasma YKL-40 levels than controls, with acute myocardial infarction patients showing the highest levels.
  • The rs10399931 variant was not associated with anthropometric/metabolic characteristics or the severity of coronary lesions.

Conclusions:

  • The rs10399931 variant is not associated with CHD susceptibility, clinical phenotypes, or lesion severity.
  • Elevated YKL-40 levels are confirmed in CHD patients and correlate with specific clinical phenotypes.
  • YKL-40 remains a relevant biomarker for understanding CHD pathophysiology and clinical manifestations.
Abstract

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...